Beta Amyloid News and Research

RSS

'White matter lesion' mapping tool can detect early signs of cognitive decline

A new tool for analyzing tissue damage seen on MRI brain scans can detect with more than 70 percent accuracy early signs of cognitive decline, new research shows.

27 Oct 2020

WSU scientists develop new method to detect Alzheimer's biomarkers

Washington State University scientists have developed a method to detect the biomarkers for Alzheimer's disease that is 10 times more sensitive than current blood testing technology.

20 Oct 2020

Magnetic resonance spectroscopy helps distinguish brain energy molecules

Researchers at Center for BrainHealth®, part of The University of Texas at Dallas, recently examined how cells in the brains of people at risk for developing Alzheimer's disease make and use energy.

24 Sep 2020

Late-life depression not linked with increased amyloid deposits in the brain

Depression in elderly people can include symptoms such as memory loss, making it hard to distinguish from the early stages of Alzheimer's disease and other types of dementia.

23 Sep 2020

Research identifies new alteration in the brain of people with Alzheimer's

Despite the important advances in research in recent years, the etiopathogenesis of Alzheimer's disease is still not fully clarified. One of the key questions is to decipher why the production of beta amyloid, the protein that produces the toxic effect and triggers the pathology, increases in the brain of people with Alzheimer's.

19 Sep 2020

HSC researchers win NIH grant to expand innovative research into Alzheimer's disease

Researchers at HSC Fort Worth were awarded a grant expected to total $45 million from the National Institute on Aging, part of the National Institutes of Health, to expand innovative research into Alzheimer's disease and the biological differences that cause the disease to disproportionately afflict Mexican Americans.

14 Sep 2020

NIH provides additional support for large scale study of Alzheimer's disease biomarkers

To meet the pressing need to better understand the prevalence, progression, and clinical impact of Alzheimer's disease among Mexican Americans, the National Institutes of Health has added funding for more biomarker measures, including positron emission tomography imaging, to the ongoing Health and Aging Brain Among Latino Elders Study.

14 Sep 2020

A potential new way of treating Alzheimer’s Disease

In this interview, Dr. Brad. L. Heckman speaks to News-Medical about a new pathway that could potentially treat Alzheimers disease.

7 Sep 2020

Sleep may serve as a marker of Alzheimer’s disease risk and progression

What would you do if you knew how long you had until Alzheimer's disease set in? Don't despair. New research from the University of California, Berkeley, suggests one defense against this virulent form of dementia -- for which no treatment currently exists -- is deep, restorative sleep, and plenty of it.

3 Sep 2020

Study provides direct link between inflammation and Alzheimer’s plaque development

Alzheimer's disease is a neurodegenerative condition that is characterized by the buildup of clumps of beta-amyloid protein in the brain.

2 Sep 2020

Diabetes blood markers linked to Alzheimer’s disease pathology, shows study

A new study published in the Journal of Alzheimer's Disease provides insight into the association of blood markers of diabetes with brain beta-amyloid accumulation among older people at risk of dementia.

18 Aug 2020

Using personalized precision medicine to treat cognitive decline

Latest research from Affirmativ Health succeeds in treating cognitive decline using personalized, precision medicine.

31 Jul 2020

Personalized, precision approach can reverse memory loss in Alzheimer’s patients

Cognitive decline is a major concern of the aging population. Already, Alzheimer's disease affects approximately 5.4 million Americans and 30 million people globally. Without effective prevention and treatment, the prospects for the future are bleak.

31 Jul 2020

Dopamine therapy improves cognitive function in patients with mild-to-moderate Alzheimer's

A study supported by the Alzheimer's Drug Discovery Foundation and published today in JAMA Network Open provides the first evidence that rotigotine, a drug that acts on dopamine transmission in the brain, improves cognitive function in patients with mild-to-moderate Alzheimer's disease.

15 Jul 2020

New treatment approach for Alzheimer's disease

A new study published in The Journal of Physiology has shown that misfolded protein build-up in the gut could contribute to the development of Alzheimer's-like symptoms in mice.

3 Jul 2020

Alzheimer’s drug could be re-purposed to reverse blood vessel damage in diabetes

Drugs that were developed to treat Alzheimer’s Disease could be re-purposed to prevent - or even reverse - the damage done to the blood vessels in people who are obese or suffer from type 2 diabetes, according to new research.

1 Jul 2020

Cancer drug nilotinib found to be safe and well-tolerated in Alzheimer's disease clinical trial

A Georgetown University Medical Center clinical trial investigating the cancer drug nilotinib in people with Alzheimer's disease finds that it is safe and well-tolerated, and researchers say the drug should be tested in a larger study to further determine its safety and efficacy as a potential disease-modifying strategy.

29 May 2020